Search Result

Results for "

Leishmania major

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Akt (2) Amyloid-β (1) Apoptosis (1) Bacterial (1) Calcium Channel (1) Cathepsin (2) COX (1) Dihydrofolate reductase (DHFR) (1) Drug Derivative (1) Heme Oxygenase (HO) (1) Hexokinase (1) IKK (2) Interleukin Related (2) Keap1-Nrf2 (1) Mitochondrial Metabolism (1) NF-κB (2) NO Synthase (3) p38 MAPK (2) Parasite (19) PKC (2) Reactive Oxygen Species (ROS) (1) Reference Standards (1) Succinate Dehydrogenase (1) Toll-like Receptor (TLR) (2)
By Research Areas:	Cancer (6) Cardiovascular Disease (2) Infection (22) Inflammation/Immunology (3) Metabolic Disease (1) Neurological Disease (1)

By Targets:

Akt (2)

Amyloid-β (1)

Apoptosis (1)

Bacterial (1)

Calcium Channel (1)

Cathepsin (2)

COX (1)

Dihydrofolate reductase (DHFR) (1)

Drug Derivative (1)

Heme Oxygenase (HO) (1)

Hexokinase (1)

IKK (2)

Interleukin Related (2)

Keap1-Nrf2 (1)

Mitochondrial Metabolism (1)

NF-κB (2)

NO Synthase (3)

p38 MAPK (2)

Parasite (19)

PKC (2)

Reactive Oxygen Species (ROS) (1)

Reference Standards (1)

Succinate Dehydrogenase (1)

Toll-like Receptor (TLR) (2)

By Research Areas:

Cancer (6)

Cardiovascular Disease (2)

Infection (22)

Inflammation/Immunology (3)

Metabolic Disease (1)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Targets Recommended: MHC CD74

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-19567

PK 11195 Maximum Cited Publications 8 Publications Verification RP 52028	Parasite	Infection
PK 11195 (RP 52028) is a ligand of translocator protein (TSPO), which targets Leishmania chemotherapy, with IC₅₀s of 14.2 μM, 8.2 μM, 3.5 μM for L. amazonensis, L. major and L. braziliensis, respectively.

HY-103353

SID 26681509 5 Publications Verification	Cathepsin Parasite	Infection Cancer
SID 26681509 is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC₅₀ of 56 nM. SID 26681509 inhibits in vitro propagation of malaria parasite *Plasmodium falciparum* and inhibits **Leishmania major with IC₅₀**s of 15.4 μM and 12.5 μM, respectively. SID 26681509 shows no inhibitory activity against cathepsin G .

HY-124481

Oleocanthal	COX Reactive Oxygen Species (ROS) NO Synthase Keap1-Nrf2 Heme Oxygenase (HO) Amyloid-β Parasite	Infection Neurological Disease Inflammation/Immunology Cancer
Oleocanthal is an orally active phenolic seciridoid compound. Oleocanthal can be extracted from olive oil. Oleocanthal inhibits COX-1 and COX-2, reduces ROS and NO, and upregulates Nrf-2 and HO-1. Oleocanthal reduces Aβ deposition. Oleocanthal exhibits anti-Leishmania activity against promastigotes and amastigotes of L. major, with IC₅₀ values of 18.7 and 87 μg/mL, respectively. Oleocanthal exhibits anticancer activity against colon, breast, liver, and melanoma cancers. Oleocanthal also exhibits anti-inflammatory and neuroprotective properties. Oleocanthal can be used in Alzheimer's disease research .

HY-P1181A

Pam2CSK4 TFA 1 Publications Verification	Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology Cancer
Pam2CSK4 TFA is a TLR2 agonist. Pam2CSK4 TFA induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 TFA activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 TFA expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 TFA acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 TFA can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis .

HY-P1181

Pam2CSK4	Toll-like Receptor (TLR) NO Synthase IKK Akt PKC NF-κB p38 MAPK Interleukin Related	Cardiovascular Disease Infection Inflammation/Immunology Cancer
Pam2CSK4 is a TLR2 agonist. Pam2CSK4 induces the expression of iNOS and NO in macrophage cell lines via TBK1 and MyD88 molecules. Pam2CSK4 activates the NF-κB and Bruton's tyrosine kinase signaling pathways in platelets, and promotes platelet-endothelial cell interactions. TLR2 activation triggered by Pam2CSK4 expands myeloid-derived suppressor cells (MDSCs) and suppresses anti-tumor immune responses in the tumor microenvironment. Pam2CSK4 acts as a Th2-polarizing adjuvant in mouse vaccine models against Leishmania major and Brugia malayi. Pam2CSK4 can be used in the research of various diseases, including thromboinflammatory diseases, sepsis, atherosclerosis, heart failure, influenza, lymphoma, melanoma, cutaneous leishmaniasis and lymphatic filariasis .

HY-149149

Incadronic acid	Bacterial	Infection Metabolic Disease Cancer
Incadronic acid inhibits growth of Dictyostelium discoideum with an IC₅₀ of 1.6 μM. Incadronic acid binds the farnesyl diphosphate synthase (FPPS) in Leishmania major with the K_i of 23 nM. Incadronic acid inhibits the bone resorption and reduces bone loss, that can be used in osteoporosis research. Incadronic acid inhibits the proliferation of cells RAW264.7, PC-3 and MCF-7 with IC₅₀ of 48 to 228.6 µM .

HY-169728

SID 24785302	Hexokinase Parasite	Infection
SID 24785302 is a hexokinase inhibitor with antiparasitic activity. SID 24785302 exhibits activity against T. brucei and Leishmania. SID 24785302 can be used for the research of mitochondrial DNA disorders and parasitic infection .

HY-151935

Antileishmanial agent-13	Parasite	Infection
Antileishmanial agent-13 is a quinoline-isatin hybrid, acts as an antileishmanial agent against L. Major Leishmania strain. Antileishmanial agent-13 acquires the antileishmanial activity via the anti-folate mechanism. Antileishmanial agent-13 has potent inhibition against both promastigote and amastigote forms with IC₅₀s of 0.604 μM and 0.508 μM, respectively .

HY-W663230

Eugenitin	Parasite	Infection
Eugenitin is a polyketide isolated from the fungus Mycoleptodiscus indicus that is related to the South American medicinal plant. Eugenitin inhibits Leishmania major with LD₅₀=39.9 μM. Eugenitin has low cytotoxicity (IC₅₀ >131 μM) against several human cancer cell lines .

HY-W009689

TbPTR1 inhibitor 2	Parasite	Infection
TbPTR1 inhibitor 2 (Compound 3a) is a PTR1 enzyme inhibitor, with IC₅₀s of 34.2 and 32.9 μM for TbPTR1 and LmPTR1. TbPTR1 inhibitor 2 has anti-parasitic activity against T. brucei (IC₅₀: 34.2 μM) .

HY-125698

3-Deoxyaphidicolin	Parasite	Infection
3-Deoxyaphidicolin exhibits phytotoxic efficacy, that inhibits root growth of lettuce seedlings. 3-Deoxyaphidicolin also exhibits leishmanicidal activity against Leishmania major and Leishmania braziliensis .

HY-175345

CYP3A4-IN-5	Parasite	Infection
CYP3A4-IN-5 (Compound 5p) is a potent Leishmania major pteridine reductase 1 (Lm PTR1) inhibitor (IC₅₀=12.77 µM). CYP3A4-IN-5 is promising for research of parasite infection .

HY-144700

Antileishmanial agent-3	Parasite	Infection
Antileishmanial agent-3 (Compound 13) is a promising growth inhibitor of Leishmania major .

HY-156132

DNDI-0690	Parasite	Infection
DNDI-0690 is a potent orally active analogue of DNDI-VL-2098, exhibiting potent activity against cutaneous leishmaniasis (CL). DNDI-0690 shows potent in vitro activity against CL-causing *Leishmania* species (EC₅₀ = 0.17 μM against visceral leishmaniasis (VL), and < 5 μM against CL-causing species). DNDI-0690 exerts effects in a mouse model of L. major CL. DNDI-0690 can be used for CL research .

HY-162155

Diarctigenin	Parasite	Infection
Diarctigenin is a selective Leishmania major dihydrofolate reductase-thymidylate synthase (LmDHFR-TS) inhibitor. Diarctigenin can be used for the research of tropical disease .

HY-103353A

SID 26681509 quarterhydrate 5 Publications Verification	Cathepsin Parasite	Infection Cancer
SID 26681509 quarterhydrate is a potent, reversible, competitive, and selective inhibitor of human cathepsin L with an IC₅₀ of 56 nM. SID 26681509 quarterhydrate inhibits in vitro propagation of malaria parasite *Plasmodium falciparum* and inhibits **Leishmania major with IC₅₀**s of 15.4 μM and 12.5 μM, respectively. SID 26681509 quarterhydrate shows no inhibitory activity against cathepsin G .

HY-149957

Antileishmanial agent-16	Parasite	Infection
Antileishmanial agent-16 (compound 14c) is an anti-Leishmania agent. Antileishmanial agent-16 has superior anti-Leishmania major promastigotes activity (IC₅₀ = 0.59 µM) and anti-Leishmania major amastigotes activity (IC₅₀ = 0.81 µM). Antileishmanial agent-16 has good safety to mammalian cells (VERO cells) .

HY-107034

Moxipraquine 349C59	Parasite	Infection
Moxipraquine is a potent insecticide against Trypanosoma cruzi. Moxipraquine effectively inhibits Leishmania major, L. mexicana mexicana and L. brasiliensis panamensis but not L.b. brasiliensis .

HY-168918

Insecticidal agent 19	Parasite Dihydrofolate reductase (DHFR)	Infection
Insecticidal agent 19 (Compound 7b) exhibits antimalarial activity by inhibiting dihydrofolate reductase-thymidylate synthase (DHFR-TS) and pteridine reductase 1 (PTR1) through the folic acid metabolic pathway. Insecticidal agent 19 inhibits Leishmania major promastigote and amastigote with IC₅₀ of 1.43 μM and 3.78 μM .

HY-19567R

PK 11195 (Standard) RP 52028 (Standard)	Parasite Reference Standards	Infection
PK 11195 (Standard) is the analytical standard of PK 11195. This product is intended for research and analytical applications. PK 11195 (RP 52028) is a ligand of translocator protein (TSPO), which targets Leishmania chemotherapy, with IC50s of 14.2 μM, 8.2 μM, 3.5 μM for L. amazonensis, L. major and L. braziliensis, respectively.

HY-19688

Sitamaquine WR 6026	Parasite Succinate Dehydrogenase Apoptosis Calcium Channel Mitochondrial Metabolism	Infection
Sitamaquine (WR 6026) is an orally active Antileishmanial agent and Succinate dehydrogenase inhibitor. Sitamaquine accumulates in the acidocalcisomes of Leishmania, induces organelle alkalization, and crosses the plasma membrane of Leishmania via temperature- and energy-independent diffusion. Sitamaquine disrupts oxidative phosphorylation in Leishmania, induces mitochondrial depolarization, oxidative stress, elevated intracellular calcium, plasma membrane depolarization, and Apoptosis-like cell death. Sitamaquine can be used in the research of leishmaniasis .

HY-N19720

Bractein	Drug Derivative Parasite	Infection
Bractein is a natural aurone flavonoid with potential antioxidant activity. Bractein shows in vitro antileishmanial activity and inhibits promastigotes and intracellular amastigotes of Leishmania donovani. Bractein exhibits no obvious cytotoxicity against mammalian macrophages with an EC₅₀ value > 25.0 μg/mL. Bractein can be used for the research of Leishmania .

Cat. No.	Product Name	Target	Research Area